用Olamkicept和安慰剂诱导治疗对活跃性结肠炎患者临床反应的影响:随机临床试验
Shenghong Zhang1, Baili Chen1, Bangmao Wang2
1Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
与安慰剂相比,Olamkicept在活跃的性结肠炎患者中显示出更大的临床反应. 需要进一步的研究来证实这种干白素-6 抑制剂的有效性和安全性.
科学领域:
- 胃肠病学
- 免疫学
- 药理学
背景情况:
- 在性结肠炎等炎症状况中发挥关键作用.
- 奥兰基cept是一种新型的融合蛋白,旨在选择性地抑制IL-6转信号.
- 向IL-6为治疗炎症性肠病提供了一个潜在的治疗策略.
研究的目的:
- 评估olamkicept作为活性性结肠炎的诱导疗法.
- 评估不同剂量的olamkicept对传统治疗反应不足的患者的疗效和安全性.
主要方法:
- 这是一项随机,双盲,安慰剂对照的2期试验,涉及91名患有性结肠炎的成年人.
- 患者在12周内每两周内输入奥兰基cept (600毫克或300毫克) 或安慰剂.
- 主要终点是第12周的临床反应,次要结果包括临床缓解和粘膜愈合.
主要成果:
- 与安慰剂 (34. 5%) 相比,600mg奥兰基cept组在第12周显示出显著更高的临床响应率 (58. 6%).
- 在300毫克的Olamkicept群体中,反应有所改善 (43. 3%),但没有达到统计学意义.
- 与安慰剂相比,在600毫克组 (16/ 25) 中观察到二次结果的统计学上显著改善.
结论:
- 在12周后,每两周服用600毫克Olamkicept显著增加了活跃性结肠炎患者的临床反应的可能性.
- 与安慰剂相比,300毫克的剂量没有显示出统计学上显著的益处.
- 需要进一步的研究来验证这些发现并评估长期的疗效和安全性.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
